Research programme: acute myeloid leukaemia vaccine - Juvaris
Latest Information Update: 16 Jul 2016
Price :
$50 *
At a glance
- Originator Juvaris BioTherapeutics
- Developer Penn State Milton S. Hershey Medical Center
- Class Vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Acute myeloid leukaemia
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acute-myeloid-leukaemia in USA
- 28 Sep 2006 Juvaris BioTherapeutics has received an SBIR grant from the National Cancer Institute for the development of a vaccine for Acute myeloid leukaemia
- 28 Sep 2004 Preclinical trials in Acute myeloid leukaemia in USA (unspecified route)